Preclinical development of a therapeutic anticancer antibody to c-Met

c-Met 治疗性抗癌抗体的临床前开发

• 批准号: nhmrc : 1113743
• 负责人: A/Pr Christoph Hagemeyer
• 金额: $ 29.04万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Development Grants
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/preclinical-development-therapeutic-c-met/663278
• 关键词: Preclinical; development; therapeutic; anticancer; antibody

Many common cancers cannot be effectively treated. A range of these cancers (e.g. gastric and lung cancer) display the molecule c-Met on their cell surface. c-Met promotes tumour growth; therefore, blocking c-Met is a promising strategy for treating these cancers. However, no antibodies or drugs that target c-Met have been licensed. The therapeutics that are being developed to target c-Met all have considerable limitations. Thus, there is an opportunity to develop a 'best-in-class' therapeutic.

许多常见的癌症无法有效治疗。一系列这些癌症（例如胃癌和肺癌）在其细胞表面上展示分子c-Met。c-Met促进肿瘤生长;因此，阻断c-Met是治疗这些癌症的有希望的策略。然而，没有靶向c-Met的抗体或药物获得许可。正在开发的靶向c-Met的治疗方法都有相当大的局限性。因此，有机会开发一种“一流”的治疗方法。